The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.
Site Search
Showing 121 - 123 of 123 results
News
|
June 9, 2021
|
4 min read
Foundation welcomes new members to advance its mission
News
|
July 8, 2021
|
7 min read
As Evan's mom, I have to constantly decide where to invest my time, especially when it comes to providing feedback. So, when offered the chance to turn my survey fatigue into something that would actually make a difference and be less of a hassle to do, I jumped at it.
Stacy Allen
|
5 min read